Abstract: Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors more than 150 proteins to the cell surface. Pathogenic variants in several genes that participate in GPI biosynthesis cause inherited GPI deficiency (IGD) disorders. Here, the inventors reported that homozygous null alleles of PIGG, a gene involved in GPI modification, are responsible for the rare Emm-negative blood phenotype. Using a panel of K562 cells defective in both the GPI-transamidase and GPI remodeling pathways, they demonstrate that the Emm antigen, whose molecular basis has remained unknown for decades, is carried only by free GPI and that its epitope is composed of the second and third ethanolamine of the GPI backbone. Importantly, the inventors show that the decrease in Emm expression in several IGD patients is indicative of GPI defects. Overall, our findings establish Emm as a novel blood group system and have important implications for understanding the biological function of human free GPI.

Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.

Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.

Abstract: The present invention relates to methods and compositions for the treatment of retinal vein occlusion.

Abstract: The present invention relates, a compound for use with selective detectors of the semiconductor resistance type which detect for nitrogenous reducing gases in the atmosphere, especially ammonia and gases containing NH and/or NH.sub.2 groups, said compound comprising the gallium nitride and, oxynitrides of tetrahedral structure according to the general formula: ##EQU1## in which: .quadrature. represents a hole, and 0.ltoreq.x.ltoreq.0.3.

Abstract: Method and apparatus intended for the filtration on a membrane of a product such as milk with a view to analysing filtration products recovered on the membrane. The method comprises the filtration under pressure and the rinsing by means of different elements without any risk of deteriorating or polluting the active filter. The apparatus which comprises two active elements (100) and (200) is particularly characterized by the combination of means for supplying a pressurized tank (3) with different liquids, and a filter holder (10) which is wedged by means of two inclined planes (P1) and (P2) driven by means of a jack (14) so that they are sealingly superposed. The invention applies particularly to the analysis of milk with a view to numbering the Clostridium Tyrobutyricum, or any other microorganism.

Abstract: Nitrides and oxynitrides which can be used as selective detectors of reducing gases in the atmosphere, and a detection device containing them. Selective detectors of nitrogen-containing reducing gases in the atmosphere, in particular ammonia and gases containing NH and/or NH.sub.2 groups, of the semiconductor resistance type, the nitrides and oxynitrides according to the invention are of tetrahedral structure and contain:a metal chosen from the group comprising Li, Na, K, Be, Mg, Ca, Sr, Ba, Zn and Mn;a second element chosen from the group comprising Si, Ge, P, Al and Ga;nitrogen and, if appropriate,oxygen.